. Primary endpoint: ICU admission (follow-up 29 days)
Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day